Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,681.12
(
-0.52%
)
US TECH 100
24,037.60
(
-0.39%
)
Dow Jones
46,600.70
(
-0.84%
)
Brent Oil
105.45
(
4.77%
)
Bitcoin
71,254.96
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: palindromy post# 75093

Friday, 03/27/2009 8:55:35 AM

Friday, March 27, 2009 8:55:35 AM

Post# of 257253

TEVA NVS MNTA: So now you are saying Novartis did not need the data at all?

NVS sought out MNTA to develop a generic version of Copaxone. MNTA’s proprietary technology allows full characterization and reverse engineering of complex drugs such as Copaxone. So, yes, I’m emphatically stating that NVS did not need to steal Teva’s Copaxone data in order to develop a generic version of Copaxone in collaboration with MNTA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now